#icotrokinra

3 stories

Clinical Trials April 1, 2026 · View digest

Icotrokinra Achieves Complete Skin Clearance Through Week 52 in Trials

Oral peptide icotrokinra delivered complete skin clearance through week 52 with a strong safety profile in the ICONIC-ADVANCE trials, presented at the American Academy of Dermatology meeting.

Clinical Trials March 29, 2026 · View digest

J&J's ICOTYDE Shows 49% Complete Skin Clearance at 52 Weeks in Psoriasis

One-year Phase 3 data at AAD 2026 show ICOTYDE (icotrokinra) achieves 49% complete clearance at Week 52, with nearly 60% in adolescents. No new safety signals.

Regulatory March 28, 2026 · View digest

FDA Approves Icotrokinra, First Oral IL-23 Receptor Blocker for Psoriasis

J&J's icotrokinra (Icotyde) approved for moderate-to-severe plaque psoriasis, with ~70% of patients achieving clear or almost clear skin by week 16.